1Department of Medical Laboratory Technology, College of Health and Medical Technology
2College of Health and Medical Technology, Middle Technical University, Baghdad, Iraq
Rheumatoid arthritis (RA) is a constant systemic autoimmune seditious disease. Although the precise etiology of disease is not known, but up to date studies demonstrate that lipocalin-2 (LCN-2) is a recognized seditious biomarker, LCN2 is involved in innate immunity by sequestrating iron that in turn limits bacterial growth that has a optimistic relationship with body mass index and a variety of metabolic syndromes.
Study intended to look the level of lipocalin-2 and their relationship with Body Mass Index BMI among patients with RA.
Patients with RA (103) that divided in to two groups(56 new early diagnosis group;47early diagnosis with treated group), were included diagnosis according to American College of Rheumatology(ACR) criteria and 25 subjects as healthy control group. All demographic(Age and Gender), clinical data(Body Mass Index BMI)and serological data(serum lipocalin-2, ACPA, CRP and RF investigated by ELISA methods. Rheumatoid Arthritis of both groups divided according to RF results in to two subgroups(seropositive 36, seronegative 20 at new early diagnosis RA group) and (seropositive 32, seronegative 15 early diagnosis RA with treated group), Mean and SE of serum lipocalin-2 level in patients with RA (9.44+1.620ng/ml), as compared to healthy control individuals (7.28 + 1.055ng/ml) were significantly higher. Positivity result of Anti-CCP in patients groups 94 (91.3%), as compare with positivity Anti-CCP 0 (0.00%) at healthy control group. No significant difference of lipocalin-2 between RF+ve and RF-ve (P>0.05) at both groups, but high significant deference among Anti-CCP and ESR between RF+ve and RF-ve of new early diagnosis RA group and high significant deference of CRP and ESR at early diagnosis RA treated group. Present study had no important correlation between lipocalin-2 levels and BMI in both groups, except among RF-ve (early diagnosis RA treated groups). These consequences point to that serum LCN-2 levels may be used as a pathogenic pointer in the early on period of the sickness but do not able to be used to pointer in the analysis of RA.
Serum Lipocalin-2, New early RA diagnosis, Body Mass Index BMI
